Precision medicine has led to the discovery of novel anti-tumor agents against various malignancies. Despite the fact that patient survival steadily increases, a concomitant increase in cardiovascular adverse effects from anti-tumor agents is also observed. Cardio-oncology, aims into identifying the exact pathomechanisms of the aforementioned cardiovascular toxicities and providing novel therapeutic regimens for their management, without hindering the antitumor potential of the anti-tumor therapies. Since the identification of doxorubicin cardiomyopathy up to the recently recognized irreversible proteasome inhibitor, carfilzomib, induced cardiomyopathy, our laboratory specializes in establishing translational models of cardiotoxicity and subsequently proposes translational and clinically applicable pharmacological interventions against the observed cardiovascular moieties. Our research has proposed the cardioprotective potential of phytochemicals such as Oleuropein and inotropes such as Levosimendan in countering doxorubicin cardiotoxicity, as well as it has established a novel translational model of carfilzomib-cardiotoxicity, in which AMPKα-activator metformin was found to exert prophylactic potential. Our scientific interest focuses on the identification of the precise molecular fingerprint of the cardiotoxicities for the discovery of novel prophylactic therapies, as well as extents in novel anti-tumor agents with proven cardiotoxic effects, such as the lately approved immune checkpoint inhibitors.